Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Biochemical and Structural Properties of Entecavir-Resistant Hepatitis B Virus Polymerase with L180M/M204V Mutations.

Journal of virology - 26 Jul 2021

Nakajima Shogo, Watashi Koichi, Kato Takanobu, Muramatsu Masamichi, Wakita Takaji, Tamura Noriko, Hattori Shin-Ichiro, Maeda Kenji, Mitsuya Hiroaki, Yasutake Yoshiaki, Toyoda Tetsuya

Abstract excerpt

Entecavir (ETV) is a widely used anti-hepatitis B virus (HBV) drug. However, the emergence of resistant mutations in HBV reverse transcriptase (RT) results in treatment failure. To understand the mechanism underlying the development of ETV resistance by HBV RT, we analyzed the L180M, M204V, and L180M/M204V mutants using a combination of biochemical and structural techniques. ETV-triphosphate (ETV-TP) exhibited...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Deoxyguanine Nucleotides
Share to Guanine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis B virus

Share to HIV Reverse Transcriptase

Share to Inhibitory Concentration 50

Share to Lamivudine

Share to Reverse Transcriptase Inhibitors

Share to RNA-Directed DNA Polymerase

Source

Open in PubMed Open full text

Identifiers

PMID: 34076480
DOI: 10.1128/JVI.02401-20
PMCID: PMC8312879

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Biochemical and Structural Properties of Entecavir-Resistant Hepatitis B Virus Polymerase with L180M/M204V Mutations.PMID 34076480Read ↗

Structural features in common of HBV and HIV-1 resistance against chirally-distinct nucleoside analogues entecavir and lamivudine.Semantic proximity Read ↗

Hepatitis B virus mutation pattern rtA181S+T184I+M204I may contribute to multidrug resistance in clinical practice: Analysis of a large cohort of Chinese patients.Semantic proximity Read ↗

Mechanism of entecavir resistance of hepatitis B virus with viral breakthrough as determined by long-term clinical assessment and molecular docking simulation.Semantic proximity Read ↗

Successful treatment of an entecavir-resistant hepatitis B virus variant.Semantic proximity Read ↗

Evolutionary trends of resistance mutational patterns of HBV reverse transcriptase over years (2002-2012) of different treatment regimens: The legacy of lamivudine/adefovir combination treatment.Semantic proximity Read ↗

Structure of the HIV-1 reverse transcriptase Q151M mutant: insights into the inhibitor resistance of HIV-1 reverse transcriptase and the structure of the nucleotide-binding pocket of Hepatitis B virus polymerase.Semantic proximity Read ↗

Impact of the rtI187V polymerase substitution of hepatitis B virus on viral replication and antiviral drug susceptibility.Semantic proximity Read ↗

Comprehensive evaluation of hepatitis B virus reverse transcriptase substitutions associated with entecavir resistanceSemantic proximity Read ↗

Understanding the molecular basis of HBV drug resistance by molecular modeling.Semantic proximity Read ↗

Entecavir resistance mutations rtL180M/T184L/M204V combined with rtA200V lead to tenofovir resistanceSemantic proximity Read ↗

Characterization of novel entecavir resistance mutations.Semantic proximity Read ↗

Treatment for hepatitis B in patients with drug resistanceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.